Quizartinib

Research use only, not for human use.

Quizartinib (AC220) is a potent, selective, second-generation FLT3 inhibitor with Kd of 1.6 nM.

Quizartinib (AC220) is a potent, selective, second-generation FLT3 inhibitor with Kd of 1.6 nM, inhibits Wt FLT3 and FLT3-ITD autophosphorylation in MV4-11cell with IC50 of 4.2 and 1.1 nM, respectively; displays excellent kinase selectivity in a KinomeScan panel of 402 kinase binding assays, also potently inhibits PDGFRA, PDGFRB and RET; inhibits MV4-11 cell proliferarion with IC50 of 0.56 nM, demonstrates antitumor efficacy in the MV4-11 tumor xenograft model.Blood Cancer Phase 3 Clinical

AC-220;AC220

Tyrosine Kinase

FLT3

FLT3(ITD);FLT3(WT);FLT3

Cancer

Blood cancer

950769-58-1

560.67

C29H32N6O4S

>98% (HPLC)

DMSO: ≥ 33 mg/mL

CC(C)(C)C1=CC(NC(=O)NC2=CC=C(C=C2)C2=CN3C(SC4=C3C=CC(OCCN3CCOCC3)=C4)=N2)=NO1

Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[4-[7-[2-(4-morpholinyl)ethoxy]imidazo[2,1-b]benzothiazol-2-yl]phenyl]-

(-20℃)

With Ice Pack

≥ 2 years